ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ipsen and Sichuan Biokin Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

IpsenSichuan Biokin Pharmaceutical
studies on the registry358146
open to participants now26100
phase 3 studies under way1636
reach primary completion within a year1550
programswith a study of their own in two years919

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIpsenSichuan Biokin Pharmaceutical
Phase 1

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%

Sichuan Biokin Pharmaceutical: 8 of its 19 programs at phase 1

  1. SI-B036phase 1
  2. BL-M24D1phase 1
  3. GNC-077phase 1
  4. Antibody-drug Conjugate BL-M17D1phase 1
  5. BL-ARC002phase 1

and 3 more — sign in to see them all

42%
Phase 244%

Sichuan Biokin Pharmaceutical: 4 of its 19 programs at phase 2

  1. BL-M08D1phase 2
  2. emfizatamabphase 2
  3. BL-M09D1phase 2
  4. glecirasibphase 2
21%
Phase 3

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%

Sichuan Biokin Pharmaceutical: 7 of its 19 programs at phase 3

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  4. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3
  5. Cytarabinephase 3

and 2 more — sign in to see them all

37%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ipsen3 readouts · 1 phase 3·

Ipsen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elifibranorphase 3 · Dec 17 · NCT06730061
··

Ipsen, Mar ’27: 1 program whose next study reaches primary completion

  1. corabotasephase 3 · Mar 26 · NCT06937931
······

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
Sichuan Biokin Pharmaceutical8 readouts · 1 phase 3

Sichuan Biokin Pharmaceutical, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. izalontamab brengitecanphase 3 · Nov 0 · NCT06118333

Sichuan Biokin Pharmaceutical, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3 · Dec 0 · NCT05924750
  2. BL-M08D1phase 2 · Dec 0 · NCT06718621
  3. emfizatamabphase 2 · Dec 0 · NCT05623982
  4. trastuzumab brengitecanphase 3 · Dec 0 · NCT06114511
·

Sichuan Biokin Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1phase 1 · Feb 28 · NCT07021066
··

Sichuan Biokin Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. BL-M09D1phase 2 · May 0 · NCT06954077

Sichuan Biokin Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. GNC-077phase 1 · Jun 0 · NCT06755242
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Sichuan Biokin Pharmaceutical

New programs 2

  • SI-B037phase 1 · first study · Nov 10
  • glecirasibphase 2 · first study · Sep 14 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionIpsenSichuan Biokin Pharmaceutical
Leukemia, Myeloid, Acuteboth · compare here

Ipsen in Leukemia, Myeloid, Acute: 1 program

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3

Their studies: Ipsen’s studies of Leukemia, Myeloid, Acute in search

Sichuan Biokin Pharmaceutical in Leukemia, Myeloid, Acute: 3 programs

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  2. Cytarabinephase 3
  3. Daunorubicinphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Leukemia, Myeloid, Acute in search

Hematologic Neoplasmsboth · compare here

Sichuan Biokin Pharmaceutical in Hematologic Neoplasms: 1 program

  1. Daunorubicinphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Hematologic Neoplasms in search

Melanomaboth · compare here

Ipsen in Melanoma: 1 program

  1. tovorafenibphase 1

Their studies: Ipsen’s studies of Melanoma in search

Sichuan Biokin Pharmaceutical in Melanoma: 1 program

  1. BL-M08D1phase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Melanoma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Ipsen 4 of 9 · Sichuan Biokin Pharmaceutical 9 of 19 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.